ArticlePloS one2009
Differential SELEX in human glioma cell lines.
Article in PloS one, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 66 citations in OpenAlex.
- Dynamics of Mitochondrial Proteome and Acetylome in Glioblastoma Cells with Contrasting Metabolic Phenotypes.International journal of molecular sciences · 2024Article
- A comparative analysis of cell surface targeting aptamers.Nature communications · 2021Article
- Retraction: Differential SELEX in Human Glioma Cell Lines.PloS one · 2020Article
- Potential and Challenges of Aptamers as Specific Carriers of Therapeutic Oligonucleotides for Precision Medicine in Cancer.Cancers · 2019Review
- Aptamers: novelty tools for cancer biology.Oncotarget · 2018Review
- Target-specific delivery of doxorubicin to human glioblastoma cell line via ssDNA aptamer.Journal of biosciences · 2018Article
- Engineered Aptamers to Probe Molecular Interactions on the Cell Surface.Biomedicines · 2017Review
- Aptamer Cell-Based Selection: Overview and Advances.Biomedicines · 2017Review
- Dual Recognition Element Lateral Flow Assay Toward Multiplex Strain Specific Influenza Virus Detection.Analytical chemistry · 2017Article
- G-quadruplex-based aptamers against protein targets in therapy and diagnostics.Biochimica et biophysica acta. General subjects · 2017Review
- Molecular Elucidation of Disease Biomarkers at the Interface of Chemistry and Biology.Journal of the American Chemical Society · 2017Article
- Evolution of Complex Target SELEX to Identify Aptamers against Mammalian Cell-Surface Antigens.Molecules (Basel, Switzerland) · 2017Review
- Development of Cell-SELEX Technology and Its Application in Cancer Diagnosis and Therapy.International journal of molecular sciences · 2016Review
- Targeting Insulin Receptor with a Novel Internalizing Aptamer.Molecular therapy. Nucleic acids · 2016Article
- Identification of an aptamer through whole cell-SELEX for targeting high metastatic liver cancers.Oncotarget · 2016Article
- Subtractive Cell-SELEX Selection of DNA Aptamers Binding Specifically and Selectively to Hepatocellular Carcinoma Cells with High Metastatic Potential.BioMed research international · 2016Article
- Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells.Oncotarget · 2015Article
- Generation of Aptamers with an Expanded Chemical Repertoire.Molecules (Basel, Switzerland) · 2015Review
- Cell-specific RNA aptamer against human CCR5 specifically targets HIV-1 susceptible cells and inhibits HIV-1 infectivity.Chemistry & biology · 2015Article
- Article
Corrections and comments
- Retraction · 2020-02-12Concerns/Issues about Results and/or Conclusions · Duplication of/in Image · Manipulation of Images · Original Data and/or Images not Provided and/or not Available ·
- Retracted
Authors and funding
5 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The hope of success of therapeutic interventions largely relies on the possibility to distinguish between even close tumor types with high accuracy. Indeed, in the last ten years a major challenge to predict the responsiveness to a given therapeutic plan has been the identification of tumor specific signatures, with the aim to reduce the frequency of unwanted side effects on oncologic patients not responding to therapy. Here, we developed an in vitro evolution-based approach, named differential whole cell SELEX, to generate a panel of high affinity nucleic acid ligands for cell surface epitopes. The ligands, named aptamers, were obtained through the iterative evolution of a random pool of sequences using as target human U87MG glioma cells. The selection was designed so as to distinguish U87MG from the less malignant cell line T98G. We isolated molecules that generate unique binding patterns sufficient to unequivocally identify any of the tested human glioma cell lines analyzed and to distinguish high from low or non-tumorigenic cell lines. Five of such aptamers act as inhibitors of specific intracellular pathways thus indicating that the putative target might be important surface signaling molecules. Differential whole cell SELEX reveals an exciting strategy widely applicable to cancer cells that permits generation of highly specific ligands for cancer biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.